Hide metadata

dc.contributor.authorJacobsen, Eva M
dc.contributor.authorTrettenes, Elin J
dc.contributor.authorWisløff, Finn
dc.contributor.authorAbildgaard, Ulrich
dc.date.accessioned2015-10-09T01:06:28Z
dc.date.available2015-10-09T01:06:28Z
dc.date.issued2006
dc.identifier.citationThrombosis Journal. 2006 Jan 25;4(1):3
dc.identifier.urihttp://hdl.handle.net/10852/46431
dc.description.abstractBackground Lupus anticoagulants prolong clotting times in phospholipid-dependent coagulation tests. Lupus Ratio assays are integrated tests for lupus anticoagulants that may be based on APTT, RVVT or dPT clotting times. If a patient is being treated with unfractionated heparin, however, the heparin prolong clotting times and the diagnosis of lupus anticoagulant is invalidated. Commercial assays may have heparin neutralising agents added to their reagents. However, the type and efficacy of the heparin neutralisation is often not documented. We wanted to test the influence and efficacy of heparin neutralisers in the Lupus Ratio assay. Methods Several heparin neutralisers were tested, and polybrene was chosen for further testing. Unfractionated heparin and/or polybrene were added to normal plasma and to plasma from patients with or without lupus anticoagulant and clotting times compared before and after the additions. Lupus anticoagulant-positive patients were given 5000 IU i.v. of unfractionated heparin and plasma was collected just before and five minutes after the injection. Lupus Ratios were calculated after polybrene was added to the postinjection samples. Results The Lupus Ratio became slightly lower when polybrene was added to plasma without heparin. Plasma heparinised in vitro and plasma from patients that had received heparin, both had Lupus Ratios nearly identical to the Lupus Ratios calculated before any additions. Conclusion By addition of polybrene to a final concentration of 7.9 μg/ml in test plasma, Lupus Ratio may be determined in lupus anticoagulant-negative as well as positive plasmas irrespective of the presence of heparin 0.0 – 1.3 U/ml.
dc.language.isoeng
dc.rightsJacobsen et al; licensee BioMed Central Ltd.
dc.rightsAttribution 2.0 Generic
dc.rights.urihttp://creativecommons.org/licenses/by/2.0/
dc.titleDetection and quantification of lupus anticoagulants in plasma from heparin treated patients, using addition of polybrene
dc.typeJournal article
dc.date.updated2015-10-09T01:06:29Z
dc.creator.authorJacobsen, Eva M
dc.creator.authorTrettenes, Elin J
dc.creator.authorWisløff, Finn
dc.creator.authorAbildgaard, Ulrich
dc.identifier.doihttp://dx.doi.org/10.1186/1477-9560-4-3
dc.identifier.urnURN:NBN:no-50615
dc.type.documentTidsskriftartikkel
dc.type.peerreviewedPeer reviewed
dc.identifier.fulltextFulltext https://www.duo.uio.no/bitstream/handle/10852/46431/1/12959_2005_Article_44.pdf
dc.type.versionPublishedVersion
cristin.articleid3


Files in this item

Appears in the following Collection

Hide metadata

Attribution 2.0 Generic
This item's license is: Attribution 2.0 Generic